Related Experiment Video

Updated: Aug 20, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease

Thomas W Yoo1, Sharyne Donfield, Alice Lail

  • 1Los Angeles Biomedical Research Institute at Harbor-University of California at Los Angeles Medical Center, Divisions of HIV Medicine and Infectious Diseases, Department of Medicine, David Geffen School of Medicine, CA 90502, USA.

The Journal of Infectious Diseases
|December 14, 2004
PubMed

Insights

Hepatitis C virus (HCV) genotype 1 is linked to higher viral loads and lower CD4 counts in children with hemophilia, increasing AIDS mortality risk. This highlights how HCV influences HIV-1 disease progression.

Area of Science:

  • Virology
  • Immunology
  • Pediatric Hematology

Background:

  • The interplay between hepatitis C virus (HCV) genotype and human immunodeficiency virus type 1 (HIV-1) disease progression remains unclear.
  • Hemophilia patients are at increased risk for both HCV and HIV-1 infections, necessitating research into their co-infection dynamics.

Purpose of the Study:

  • To investigate the impact of HCV genotype on disease progression in children and adolescents with hemophilia, co-infected with or without HIV-1.
  • To determine if HCV genotype influences viral load, CD4(+) T cell counts, and AIDS-related mortality.

Main Methods:

  • Analysis of data from 207 HIV-1-infected and 126 HIV-1-uninfected children with hemophilia from the Hemophilia Growth and Development Study.
  • Longitudinal follow-up over 7 years, comparing HCV RNA levels, HIV-1 RNA levels, CD4(+) T cell counts, and mortality rates between HCV genotype 1 and non-genotype 1 groups.

Main Results:

  • HCV genotype 1 was associated with significantly higher mean HCV RNA levels in both HIV-1-infected and uninfected participants.
  • Participants with HCV genotype 1 exhibited lower mean CD4(+) T cell counts and percentages.
  • HCV genotype 1 infection increased the risk of progression to AIDS-related mortality (HR, 2.44; P=.037).

Conclusions:

  • HCV infection and specific genotypes, particularly genotype 1, significantly influence the natural history of HCV and HIV-1 disease in children with hemophilia.
  • HCV genotype 1 is a critical factor associated with poorer clinical outcomes, including reduced CD4 counts and increased mortality.
  • Further research is warranted to understand the mechanisms driving these associations and to inform treatment strategies.

More Related Videos

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...